- Home
- LXEO vs RNAC Comparison
LXEO vs RNAC Comparison
Compare LXEO & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEO | RNAC |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.1M | 283.2M |
| IPO Year | 2023 | 2016 |
Fundamental Metrics
Financial Performance| Metric | LXEO | RNAC |
|---|---|---|
| Price | $4.69 | $9.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $18.44 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 803.0K | 439.1K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $654,000.00 | ★ $2,797,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.60 | $5.60 |
| 52 Week High | $10.99 | $14.56 |
Technical Indicators
Market Signals| Indicator | LXEO | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 58.59 |
| Support Level | $4.44 | $9.13 |
| Resistance Level | $5.34 | $9.82 |
| Average True Range (ATR) | 0.35 | 1.19 |
| MACD | 0.08 | 0.13 |
| Stochastic Oscillator | 57.25 | 69.50 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.